Qoniq
Founded 2019 · 15 employees on LinkedIn · 2 known investors
Qoniq provides data analysis and knowledge synthesis tools for Medical and Scientific Affairs professionals, helping them work with complex scientific datasets while augmenting rather than replacing human expertise.
Also known as Huma AI · Huma.ai
Investors · 2
Company profile
researched Aug 2026Qoniq (pronounced "Konik") is an artificial intelligence platform built for Medical Affairs and Scientific Affairs teams at life sciences organizations, including biotechnology, diagnostics and medical device companies. The platform applies domain-specific scientific reasoning across structured and unstructured data sources such as published literature, CRM data, survey responses and advisory board outputs, with the aim of surfacing patterns, relationships and emerging themes across large evidence sets that are difficult to identify through manual review.
Alongside its analytics, the company pairs clients with consultants who configure and adapt analytical workflows, engineer prompts, and help ensure outputs meet medical, legal and regulatory review standards. Product areas listed by the company include medical congress reporting, weekly scientific literature reports, CRM insight generation, standard medical response letters, and post-market surveillance. Deliverables include Standard Response Letters, PRISMA reviews and KOL reports, with the company stating that traceability is maintained between generated insights and their underlying evidence sources. Published case studies cover post-marketing surveillance using generative AI and a pharmaceutical company shifting Medical Affairs work from reactive to proactive.
Business model
Qoniq sells a software platform combined with consulting and deployment services to life sciences organizations, using a concierge deployment model in which its staff work with client Medical Affairs teams to configure workflows and prompts rather than delivering a purely self-service tool. Engagement begins through requested consultations and demos.
Latest developments
On April 28, 2026, the company announced its rebrand from Huma.ai to Qoniq and the launch of a next-generation platform for Medical Affairs, naming Susan Shiff, PhD, MBA as CEO and Steven Skolsky as Board Chair. John Crumpler, General Partner at Hatteras Venture Partners, commented on the company's transformation in the same announcement.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company positions itself against general-purpose AI tools by focusing exclusively on Medical Affairs workflows, evidentiary hierarchies and scientific standards, and by offering hands-on deployment support in what its announcement describes as a crowded market.
Stated points of difference include domain-specific scientific reasoning tuned to Medical Affairs rather than general-purpose AI, single-tenant data isolation, traceability between insights and source evidence, and a concierge deployment model in which Qoniq staff configure workflows and prompts with client teams.
Technology
The platform combines tailored AI systems with scientific-domain reasoning to analyze large volumes of publications and datasets, identify patterns and connections, and generate industry-standard documents. It ingests both structured and unstructured inputs, including published literature, CRM records, survey responses and ad board outputs. A single-tenant architecture is used so that each client's data remains isolated, and the company states its outputs preserve links between conclusions and the supporting evidence.
Go-to-market
Direct enterprise sales driven through consultation requests and product demonstrations on the company website, supported by downloadable product materials and published customer case studies, with close post-sale partnering during deployment.
Medical Affairs and Scientific Affairs teams at life sciences organizations, including pharmaceutical, biotechnology, diagnostics and medical device companies; the company describes its customers as teams carrying full Medical Affairs responsibilities without the internal resources to build and manage custom AI infrastructure.
Geography
The rebrand announcement was issued from Cary, North Carolina, United States.
History
The company previously operated as Huma.ai. In an announcement dated April 28, 2026, it stated that over the preceding year it had brought on new executive leadership, rebuilt its platform architecture and deepened its Medical Affairs domain expertise, and it introduced the Qoniq name together with a next-generation platform.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsThe rebrand announcement identified Susan Shiff as CEO and Steven Skolsky as Board Chair, and referenced new executive leadership brought on over the prior year.
Formerly known as Huma.ai, the company announced a rebrand to Qoniq alongside the launch of an AI platform built exclusively for Medical Affairs teams at life sciences organizations. The announcement noted that over the prior year the company added new executive leadership, rebuilt its platform architecture, and deepened its Medical Affairs domain expertise.
Platform applies domain-specific scientific reasoning across structured and unstructured data including published literature, CRM data, survey responses and ad board outputs, with single-tenant architecture isolating each client's data.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Qoniqqoniq.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Qoniq do?
- Qoniq, formerly Huma.ai, sells an AI platform and expert services for life sciences Medical Affairs evidence analysis.
- Who are Qoniq's investors?
- Qoniq's investors include Excelerate Health Ventures, Fusion.